Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Identifieur interne : 001F15 ( PubMed/Corpus ); précédent : 001F14; suivant : 001F16Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Auteurs : Robert A. Hauser ; Michel Panisset ; Giovanni Abbruzzese ; Linda Mancione ; Nalina Dronamraju ; Algirdas KakariekaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Carbidopa (therapeutic use), Catechols (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Nitriles (therapeutic use), Outcome Assessment (Health Care) (methods), Parkinson Disease (drug therapy), Severity of Illness Index.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Catechols, Levodopa, Nitriles.
- drug therapy : Parkinson Disease.
- methods : Outcome Assessment (Health Care).
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
We performed a 39-week, randomized, double-blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty-three patients with early PD warranting levodopa were randomly assigned to treatment with LCE 100/25/200 or LC 100/25 three-times daily. The adjusted mean difference in total Unified Parkinson's disease Rating Scale (UPDRS) Parts II and III between groups using the analysis of covariance model (prespecified primary outcome measure) was 1.7 (standard error = 0.84) points favoring LCE (P = 0.045). Significantly greater improvement with LCE compared with LC was also observed in UPDRS Part II activities of daily living (ADL) scores (P = 0.025), Schwab and England ADL scores (blinded rater, P = 0.003; subject, P = 0.006) and subject-reported Clinical Global Impression (CGI) scores (P = 0.047). There was no significant difference in UPDRS Part III or investigator-rated CGI scores. Wearing-off was observed in 29 (13.9%) subjects in the LCE group and 43 (20.0%) in the LC group (P = 0.099). Dyskinesia was observed in 11 (5.3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications.
DOI: 10.1002/mds.22343
PubMed: 19058133
Links to Exploration step
pubmed:19058133Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA. rhauser@health.usf.edu</nlm:affiliation></affiliation></author><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name></author><author><name sortKey="Abbruzzese, Giovanni" sort="Abbruzzese, Giovanni" uniqKey="Abbruzzese G" first="Giovanni" last="Abbruzzese">Giovanni Abbruzzese</name></author><author><name sortKey="Mancione, Linda" sort="Mancione, Linda" uniqKey="Mancione L" first="Linda" last="Mancione">Linda Mancione</name></author><author><name sortKey="Dronamraju, Nalina" sort="Dronamraju, Nalina" uniqKey="Dronamraju N" first="Nalina" last="Dronamraju">Nalina Dronamraju</name></author><author><name sortKey="Kakarieka, Algirdas" sort="Kakarieka, Algirdas" uniqKey="Kakarieka A" first="Algirdas" last="Kakarieka">Algirdas Kakarieka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22343</idno><idno type="RBID">pubmed:19058133</idno><idno type="pmid">19058133</idno><idno type="wicri:Area/PubMed/Corpus">001F15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA. rhauser@health.usf.edu</nlm:affiliation></affiliation></author><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name></author><author><name sortKey="Abbruzzese, Giovanni" sort="Abbruzzese, Giovanni" uniqKey="Abbruzzese G" first="Giovanni" last="Abbruzzese">Giovanni Abbruzzese</name></author><author><name sortKey="Mancione, Linda" sort="Mancione, Linda" uniqKey="Mancione L" first="Linda" last="Mancione">Linda Mancione</name></author><author><name sortKey="Dronamraju, Nalina" sort="Dronamraju, Nalina" uniqKey="Dronamraju N" first="Nalina" last="Dronamraju">Nalina Dronamraju</name></author><author><name sortKey="Kakarieka, Algirdas" sort="Kakarieka, Algirdas" uniqKey="Kakarieka A" first="Algirdas" last="Kakarieka">Algirdas Kakarieka</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Carbidopa (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitriles (therapeutic use)</term><term>Outcome Assessment (Health Care) (methods)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Catechols</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Outcome Assessment (Health Care)</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a 39-week, randomized, double-blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty-three patients with early PD warranting levodopa were randomly assigned to treatment with LCE 100/25/200 or LC 100/25 three-times daily. The adjusted mean difference in total Unified Parkinson's disease Rating Scale (UPDRS) Parts II and III between groups using the analysis of covariance model (prespecified primary outcome measure) was 1.7 (standard error = 0.84) points favoring LCE (P = 0.045). Significantly greater improvement with LCE compared with LC was also observed in UPDRS Part II activities of daily living (ADL) scores (P = 0.025), Schwab and England ADL scores (blinded rater, P = 0.003; subject, P = 0.006) and subject-reported Clinical Global Impression (CGI) scores (P = 0.047). There was no significant difference in UPDRS Part III or investigator-rated CGI scores. Wearing-off was observed in 29 (13.9%) subjects in the LCE group and 43 (20.0%) in the LC group (P = 0.099). Dyskinesia was observed in 11 (5.3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19058133</PMID><DateCreated><Year>2009</Year><Month>05</Month><Day>11</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>541-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22343</ELocationID><Abstract><AbstractText>We performed a 39-week, randomized, double-blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty-three patients with early PD warranting levodopa were randomly assigned to treatment with LCE 100/25/200 or LC 100/25 three-times daily. The adjusted mean difference in total Unified Parkinson's disease Rating Scale (UPDRS) Parts II and III between groups using the analysis of covariance model (prespecified primary outcome measure) was 1.7 (standard error = 0.84) points favoring LCE (P = 0.045). Significantly greater improvement with LCE compared with LC was also observed in UPDRS Part II activities of daily living (ADL) scores (P = 0.025), Schwab and England ADL scores (blinded rater, P = 0.003; subject, P = 0.006) and subject-reported Clinical Global Impression (CGI) scores (P = 0.047). There was no significant difference in UPDRS Part III or investigator-rated CGI scores. Wearing-off was observed in 29 (13.9%) subjects in the LCE group and 43 (20.0%) in the LC group (P = 0.099). Dyskinesia was observed in 11 (5.3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA. rhauser@health.usf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Abbruzzese</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mancione</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dronamraju</LastName><ForeName>Nalina</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kakarieka</LastName><ForeName>Algirdas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><CollectiveName>FIRST-STEP Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00134966</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002396">Catechols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>4975G9NM6T</RegistryNumber><NameOfSubstance UI="C071192">entacapone</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002396">Catechols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017063">Outcome Assessment (Health Care)</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Anwar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cakmur</LastName><ForeName>Raif</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chou</LastName><ForeName>Kelvin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cloutier</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cunha</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>Hiren</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Djaldetti</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dostal</LastName><ForeName>Vaclav</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elibol</LastName><ForeName>Bulent</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emre</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiszer</LastName><ForeName>Urszula</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giladi</LastName><ForeName>Nir</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gollomp</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodridge</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimes</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guttman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassin</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez-Shahed</LastName><ForeName>Joohi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanovsky</LastName><ForeName>Petr</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kraft</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lafontaine</LastName><ForeName>Anne-Louise</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewitt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mach</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzeo</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meco</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgante</LastName><ForeName>Letterio</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Opala</LastName><ForeName>Grzegorz</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezzoli</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pourcher</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabey</LastName><ForeName>Jose Martin</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivest</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa</LastName><ForeName>Mario Miguel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossen</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudzinska</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruzicka</LastName><ForeName>Evzen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sauter</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silver</LastName><ForeName>Dee</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Dwight</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veloso</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappia</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zesiewicz</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22343</ArticleId><ArticleId IdType="pubmed">19058133</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19058133
|texte= Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19058133" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |